A detailed history of Jpmorgan Chase & CO transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 41,374 shares of AVXL stock, worth $302,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,374
Previous 47,909 13.64%
Holding current value
$302,030
Previous $243,000 28.4%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$3.39 - $5.02 $22,153 - $32,805
-6,535 Reduced 13.64%
41,374 $174,000
Q1 2024

May 10, 2024

SELL
$4.55 - $6.75 $75,197 - $111,557
-16,527 Reduced 25.65%
47,909 $243,000
Q4 2023

Feb 12, 2024

BUY
$5.04 - $9.95 $1,774 - $3,502
352 Added 0.55%
64,436 $599,000
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $31,426 - $44,957
4,798 Added 8.09%
64,084 $419,000
Q2 2023

Aug 11, 2023

BUY
$7.66 - $9.5 $11,980 - $14,858
1,564 Added 2.71%
59,286 $481,000
Q1 2023

May 18, 2023

BUY
$8.32 - $11.75 $440,743 - $622,444
52,974 Added 1115.71%
57,722 $494,000
Q1 2023

May 11, 2023

SELL
$8.32 - $11.75 $326,360 - $460,905
-39,226 Reduced 89.2%
4,748 $40,000
Q4 2022

Feb 13, 2023

BUY
$7.65 - $14.43 $1,935 - $3,650
253 Added 0.58%
43,974 $407,000
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $26,931 - $38,914
3,026 Added 7.44%
43,721 $452,000
Q2 2022

Aug 11, 2022

SELL
$7.31 - $12.84 $5,738 - $10,079
-785 Reduced 1.89%
40,695 $408,000
Q1 2022

May 11, 2022

BUY
$9.74 - $17.69 $79,293 - $144,014
8,141 Added 24.42%
41,480 $511,000
Q4 2021

Feb 10, 2022

BUY
$16.88 - $23.31 $147,548 - $203,752
8,741 Added 35.54%
33,339 $578,000
Q3 2021

Nov 12, 2021

BUY
$16.82 - $25.75 $413,738 - $633,398
24,598 New
24,598 $440,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $569M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.